XECHEM INTERNATIONAL INC
8-K, 1996-09-10
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: MK RAIL CORP, 8-K, 1996-09-10
Next: RENAL CARE GROUP INC, DEFM14A, 1996-09-10



                      SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C.  20549

                                   FORM 8-K

                                CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934




Date of Report (Date of Earliest Event Reported):  August 29, 1996



                          Xechem International, Inc.
            (Exact name of Registrant as Specified in its Charter)



      Delaware                  0-23788                   22-3284803
(State of Incorporation) (Commission File No.) (IRS Employer Identification No.)



                       100 Jersey Avenue, Bldg. B, #310
                          New Brunswick, N.J. 08901
                   (Address of Principal Executive Offices)


Registrant's telephone number, including area code:      (908) 247-3300

                                      1

<PAGE>



Item 5.  Other Events.

      On August 29, 1996,  Xechem  International,  Inc. (the  "Company") and its
wholly-owned  subsidiary,   XetaPharm,   Inc.  ("XetaPharm"),   entered  into  a
Memorandum  of  Understanding  (the  "MOU")  with  Petron  International,   Inc.
("Petron"),  wherein  Petron  agreed to  purchase  96 shares of common  stock of
XetaPharm (48.98% of the shares to be outstanding) for a total of $500,000.  The
MOU provides that Petron will pay for the XetaPharm  shares as follows:  $50,000
on or before  September  5, 1996;  $100,000 on September  30, 1996;  $150,000 on
October 30, 1996;  and $200,000 on November 30, 1996. The Company agreed to make
its existing facility and personnel  available to XetaPharm at a cost of $25,000
per month for twelve months ending August 31, 1997.

      After each  payment,  Petron will receive that number of XetaPharm  shares
for which full  payment has been made.  The MOU also  provides  that all current
employees of the Company working primarily on XetaPharm matters will become full
time XetaPharm  employees.  XetaPharm's  board of directors will be comprised of
three  persons,  Dr.  Ramesh  Pandey  (Chairman),  Yogi Sarin and a third person
designated by Dr. Pandey and Petron.

      In the MOU,  Petron  also agreed to  purchase  1,250,000  shares of Xechem
common stock for a total of $500,000.  The MOU provides that Petron will pay for
the  Company's  shares as follows:  $50,000 on or before  September  5, 1996 and
$50,000 on the first day of each of the following nine months.

      After each  payment,  Petron will  receive that number of shares for which
full  payment  has been  made.  Petron  has  granted  the  Company  an option to
repurchase  up to 250,000 of such  shares any time  before  August 29, 1999 at a
price of $0.75 per share. The MOU further provides that the Company will use its
best  efforts  to cause  Mr.  Sarin to be  added  as a  member  of its  board of
directors  and to nominate  him to a seat on the board of  directors at its next
annual meeting,  provided that Petron is not in default of its obligations under
the MOU.

              Petron is a privately held engineering  consulting firm, for which
there is no publicly available financial information. There can be no assurances
that Petron will meet all of its obligations under the MOU.

                                      2

<PAGE>



                                  SIGNATURES

      Pursuant to the  requirements  of the Securities and Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                           Xechem International, Inc.


                                    By: /s/ Dr. Ramesh C. Pandey
                                      Dr. Ramesh C. Pandey, President and Chief
                                      Executive Officer




Dated:  September 9, 1996





                                      3

<PAGE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission